Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$6.30
+1.6%
$6.55
$3.80
$9.87
$826.94M1.38724,580 shs1.21 million shs
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
$23.32
-0.3%
$23.28
$14.10
$26.01
$2.90B0.5618,868 shs353,117 shs
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$1.77
+2.9%
$3.01
$1.25
$14.55
$482.04M1.999.99 million shs13.42 million shs
10x Genomics, Inc. stock logo
TXG
10x Genomics
$25.99
-1.5%
$34.19
$24.60
$63.57
$3.10B1.941.57 million shs1.25 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-1.12%0.00%-10.27%-25.12%-30.06%
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
-0.30%+1.65%+1.08%-3.39%-1.14%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
+2.38%-2.27%-52.35%-74.10%-85.56%
10x Genomics, Inc. stock logo
TXG
10x Genomics
+4.06%+0.38%-29.38%-46.73%-51.47%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
1.66 of 5 stars
3.30.00.00.02.23.30.6
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
1.0695 of 5 stars
2.04.00.00.03.50.00.6
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
3.106 of 5 stars
4.31.00.00.02.91.71.3
10x Genomics, Inc. stock logo
TXG
10x Genomics
4.5263 of 5 stars
4.31.00.04.82.43.30.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
2.60
Moderate Buy$9.0042.86% Upside
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
2.00
Hold$26.0011.49% Upside
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
2.53
Moderate Buy$7.68334.00% Upside
10x Genomics, Inc. stock logo
TXG
10x Genomics
2.58
Moderate Buy$48.5086.61% Upside

Current Analyst Ratings

Latest TXG, PACB, OLK, and CTKB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/10/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$3.00 ➝ $2.00
5/1/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$52.00 ➝ $30.00
5/1/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$30.00 ➝ $26.00
5/1/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$45.00 ➝ $36.00
5/1/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$63.00 ➝ $53.00
5/1/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$57.00 ➝ $32.00
4/29/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$65.00 ➝ $50.00
4/22/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral
4/18/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$9.00 ➝ $2.50
4/18/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$7.00 ➝ $2.50
4/18/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$15.00 ➝ $8.00
(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$193.01M4.28$0.03 per share246.60$2.90 per share2.17
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
$169.60M17.10N/AN/A$4.04 per share5.77
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$200.52M2.40N/AN/A$2.62 per share0.68
10x Genomics, Inc. stock logo
TXG
10x Genomics
$618.73M5.01N/AN/A$6.22 per share4.18

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$12.15M-$0.09N/A90.00N/A-6.29%-1.40%-1.13%8/13/2024 (Estimated)
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
-$31.60M-$0.25N/A583.00N/A-18.63%-6.50%-5.63%N/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$306.73M-$1.21N/AN/AN/A-152.97%-40.23%-15.24%8/7/2024 (Estimated)
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$255.10M-$2.23N/AN/AN/A-42.20%-30.85%-24.17%8/1/2024 (Estimated)

Latest TXG, PACB, OLK, and CTKB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024Q1 2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$0.26-$0.26N/A-$0.23$38.78 million$38.81 million  
4/30/2024Q1 2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$0.50-$0.50N/A-$0.50$142.24 million$141.01 million    
3/25/2024Q4 2023
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
$0.14-$0.06-$0.20-$0.06$82.80 million$68.55 million
3/13/2024Q4 2023
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/A$0.04+$0.04$0.04$56.66 million$58.23 million
2/15/202412/31/2023
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$0.29-$0.27+$0.02-$0.23$57.96 million$58.36 million    
2/15/2024Q4 2023
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$0.36-$0.41-$0.05-$0.41$182.73 million$183.98 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/AN/AN/AN/AN/A
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
N/AN/AN/AN/AN/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/AN/AN/AN/AN/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/A
6.97
5.89
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
N/A
4.75
3.55
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
1.27
7.81
7.21
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/A
5.22
4.45

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
69.46%
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
30.19%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
84.68%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
676131.26 million110.39 millionOptionable
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
707124.34 millionN/AOptionable
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
796272.34 million268.53 millionOptionable
10x Genomics, Inc. stock logo
TXG
10x Genomics
1,259119.17 million106.48 millionOptionable

TXG, PACB, OLK, and CTKB Headlines

SourceHeadline
Cathie Woods Latest Buys: 3 Stocks the ARK Invest CEO Cant Get Enough OfCathie Wood's Latest Buys: 3 Stocks the ARK Invest CEO Can't Get Enough Of
investorplace.com - May 6 at 1:04 PM
International Markets and 10x Genomics (TXG): A Deep Dive for InvestorsInternational Markets and 10x Genomics (TXG): A Deep Dive for Investors
zacks.com - May 6 at 10:11 AM
Vestmark Advisory Solutions Inc. Makes New $4.33 Million Investment in 10x Genomics, Inc. (NASDAQ:TXG)Vestmark Advisory Solutions Inc. Makes New $4.33 Million Investment in 10x Genomics, Inc. (NASDAQ:TXG)
marketbeat.com - May 4 at 2:39 PM
Research Analysts Issue Forecasts for 10x Genomics, Inc.s Q2 2024 Earnings (NASDAQ:TXG)Research Analysts Issue Forecasts for 10x Genomics, Inc.'s Q2 2024 Earnings (NASDAQ:TXG)
americanbankingnews.com - May 4 at 1:42 AM
Q2 2024 Earnings Estimate for 10x Genomics, Inc. Issued By William Blair (NASDAQ:TXG)Q2 2024 Earnings Estimate for 10x Genomics, Inc. Issued By William Blair (NASDAQ:TXG)
marketbeat.com - May 3 at 7:28 AM
10x Genomics (NASDAQ:TXG) PT Lowered to $36.0010x Genomics (NASDAQ:TXG) PT Lowered to $36.00
americanbankingnews.com - May 3 at 5:14 AM
10x Genomics (NASDAQ:TXG) Stock Rating Lowered by TD Cowen10x Genomics (NASDAQ:TXG) Stock Rating Lowered by TD Cowen
americanbankingnews.com - May 3 at 5:14 AM
The Goldman Sachs Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $26.00The Goldman Sachs Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $26.00
americanbankingnews.com - May 3 at 5:14 AM
Stifel Nicolaus Lowers 10x Genomics (NASDAQ:TXG) Price Target to $53.00Stifel Nicolaus Lowers 10x Genomics (NASDAQ:TXG) Price Target to $53.00
americanbankingnews.com - May 3 at 5:14 AM
10x Genomics (NASDAQ:TXG) PT Lowered to $30.0010x Genomics (NASDAQ:TXG) PT Lowered to $30.00
americanbankingnews.com - May 3 at 5:14 AM
10x Genomics to Present at the BofA Securities 2024 Healthcare Conference10x Genomics to Present at the BofA Securities 2024 Healthcare Conference
prnewswire.com - May 2 at 4:05 PM
TD Cowen Downgrades 10x Genomics (TXG)TD Cowen Downgrades 10x Genomics (TXG)
msn.com - May 2 at 7:37 AM
10x Genomics First Quarter 2024 Earnings: In Line With Expectations10x Genomics First Quarter 2024 Earnings: In Line With Expectations
finance.yahoo.com - May 2 at 7:37 AM
10x Genomics, Inc: 10x Genomics Reports First Quarter 2024 Financial Results10x Genomics, Inc: 10x Genomics Reports First Quarter 2024 Financial Results
finanznachrichten.de - May 2 at 2:37 AM
10x Genomics (NASDAQ:TXG) Sets New 12-Month Low After Analyst Downgrade10x Genomics (NASDAQ:TXG) Sets New 12-Month Low After Analyst Downgrade
americanbankingnews.com - May 2 at 1:18 AM
10x Genomics (NASDAQ:TXG) Given New $30.00 Price Target at UBS Group10x Genomics (NASDAQ:TXG) Given New $30.00 Price Target at UBS Group
marketbeat.com - May 1 at 2:32 PM
10x Genomics (NASDAQ:TXG) Hits New 12-Month Low After Analyst Downgrade10x Genomics (NASDAQ:TXG) Hits New 12-Month Low After Analyst Downgrade
marketbeat.com - May 1 at 11:34 AM
Analysts’ Opinions Are Mixed on These Healthcare Stocks: 10x Genomics (TXG), Zoetis (ZTS) and Blueprint Medicines (BPMC)Analysts’ Opinions Are Mixed on These Healthcare Stocks: 10x Genomics (TXG), Zoetis (ZTS) and Blueprint Medicines (BPMC)
markets.businessinsider.com - May 1 at 8:41 AM
10x Genomics (NASDAQ:TXG) Downgraded by TD Cowen10x Genomics (NASDAQ:TXG) Downgraded by TD Cowen
marketbeat.com - May 1 at 8:32 AM
Canaccord Genuity Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $50.00Canaccord Genuity Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $50.00
americanbankingnews.com - May 1 at 5:32 AM
10x Genomics Inc (TXG) (Q1 2024) Earnings Call Transcript Highlights: Diverse Revenue Streams ...10x Genomics Inc (TXG) (Q1 2024) Earnings Call Transcript Highlights: Diverse Revenue Streams ...
finance.yahoo.com - May 1 at 3:41 AM
Curio Bioscience Reports Clarifying Decision From European Unified Patent Court (UPC)Curio Bioscience Reports Clarifying Decision From European Unified Patent Court (UPC)
businesswire.com - May 1 at 1:01 AM
10x Genomics: Q1 Earnings Snapshot10x Genomics: Q1 Earnings Snapshot
sfgate.com - April 30 at 10:41 PM
TXG Stock Earnings: 10x Genomics Meets EPS, Misses Revenue for Q1 2024TXG Stock Earnings: 10x Genomics Meets EPS, Misses Revenue for Q1 2024
markets.businessinsider.com - April 30 at 10:41 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cytek Biosciences logo

Cytek Biosciences

NASDAQ:CTKB
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Olink Holding AB (publ) logo

Olink Holding AB (publ)

NASDAQ:OLK
Olink Holding AB (publ) develops, produces, markets, and sells biotechnological products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research. The company's products include Olink Explore that consist of Explore 372 and Explore 384 for cardiovascular and metabolic, oncology, neurology, and inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. Its products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and data analysis and bioinformatics services. In addition, the company offers Olink normalized protein expression (NPX) data processing software, a purpose-built software that enable users to import data, perform data analysis including visualizations, and statistical modelling; and Olink Insight, a cloud platform for Olink community to accelerate proteomics. It sells its products and services through its own direct sales force in Sweden, the United States, rest of the Americas, rest of Europe, the Middle East, Africa, Japan, and internationally. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. Olink Holding AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.
Pacific Biosciences of California logo

Pacific Biosciences of California

NASDAQ:PACB
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
10x Genomics logo

10x Genomics

NASDAQ:TXG
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.